nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

29.07.2021 | Original Article

Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study

verfasst von: Motohiko Sato, Masaaki Inaba, Shinsuke Yamada, Masanori Emoto, Yoshiteru Ohno, Yoshihiro Tsujimoto

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Romosozumab reportedly increases bone mineral density (BMD) potently but might adversely affect cardiovascular disease (CVD). We evaluated the efficacy of romosozumab in osteoporotic HD patients with a high risk of fracture.

Materials and methods

This was a single-center 1-year study in Japanese HD patients. Among 96 HD romosozumab-treated HD patients with high risk of fracture, 76 HD patients completed 1 year of subcutaneous administration of romosozumab (210 mg/4 weeks) for 1 year. Romosozumab-untreated HD patients (n = 55) were also included. Changes in BMD and serum markers, together with fracture occurrence, and CVD events, were monitored.

Results

During romosozumab treatment of 76 HD patients, BMD time-dependently increased significantly by 15.3% ± 12.9% at the lumbar spine (L1–4), and 7.2% ± 8.3% at the femoral neck at 1 year. Serum BAP and total P1NP increased significantly and serum TRACP-5b decreased at 4 weeks. Fragility fractures occurred in three (3.8%) patients. Hypocalcemia occurred at 4–48 weeks despite the increased dosing of active vitamin-D derivatives, but without any symptom. New CVD events occurred in 5.2% of romosozumab-treated HD patients and10.9% in romosozumab-untreated HD patients.

Conclusions

BMD was increased significantly during romosozumab treatment at the lumbar spine, and the femoral neck, respectively, at 1 year in HD patients. Hypocalcemia occurred but without any intolerable event. There was no apparent increase in CVD events during 1 year of study, suggesting romosozumab as a promising agent for HD patients with severe osteoporosis.

Nitta K, Goto S, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, Wada A, Hamano T, Hoshino J, Joki N (2020) Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality. Ren Replace Ther 6:41CrossRef

Vilaca T, Salam S, Schini M, Harnan S, Sutton A, Poku E, Allen IE, Cummings SR, Eastell R (2020) Risks of hip and nonvertebral fractures in patients with CKD G3a–G5D: a systematic review and meta-analysis. Am J Kidney Dis 76:521–532CrossRef

Maeno Y, Inaba M, Okuno S, Kohno K, Maekawa K, Yamakawa T, Ishimura E, Nishizawa Y (2009) Significant association of fracture of the lumbar spine with mortality in female hemodialysis patients: a prospective observational study. Calcif Tissue Int 85:310–316CrossRef

Kanazawa I, Inaba M, Inoue D, Uenishi K, Saito M, Shiraki M, Suzuki A, Takeuchi Y, Hagino H, Fujiwara S, Sugimoto T (2020) Executive summary of clinical practice guide on fracture risk in lifestyle diseases. J Bone Miner Metab 38:746–758CrossRef

Kidney Disease (2009) Improving global outcomes (KDIGO) CKD–MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD–MBD). Kidney Int Suppl 113:S1–S130

Wakasugi M, Kazama JJ, Wada A, Hamano T, Masakane I, Narita I (2020) Long-term excess mortality after hip fracture in hemodialysis patients: a nationwide cohort study in Japan. J Bone Miner Metab 38:718–729CrossRef

Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, Pisoni RL (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166–173CrossRef

Hickson LJ, Farah WH, Johnson RL, Thorsteinsdottir B, Ubl DS, Yuan BJ, Albright R, Rule AD, Habermann EB (2018) Death and postoperative complications after hip fracture repair: dialysis effect. Kidney Int Rep. 3:1294–1303CrossRef

Pharmaceuticals and Medical Devices Agency (2019) Evenity subcutaneous injection 105 mg. Prescribing information https://www.pmda.go.jp/PmdaSearch/iyakuDetail/112922_3999449G1025_1_03#WARNINGS (in Japanese)

10.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543CrossRef

11.

Fabre S, Funck-Brentano T, Cohen-Solal M (2020) Anti-sclerostin antibodies in osteoporosis and other bone diseases. J Clin Med 9:3439CrossRef

12.

Fixen C, Tunoa J (2021) Romosozumab: a review of efficacy, safety, and cardiovascular risk. Curr Osteoporos Rep 19(1):15–22. https://doi.org/10.1007/s11914-020-00652-wCrossRefPubMed

13.

Sakura M, Inaba M, Yoda K, Ichii M, Yamada S, Yamakawa T, Ishimura E, Okuno S, Shoji S (2016) High coronary heart disease risk in hemodialysis patients with central sleep apnea: a pilot study. Am J Nephrol 44:388–395CrossRef

14.

Inaba M, Okuno S, Nagayama H, Yamada S, Ishimura E, Imanishi Y, Shoji S (2015) Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone. J Ren Nutr 25:242–246CrossRef

15.

Japan Osteoporosis Society (2015) Guideline for prevention and treatment of osteoporosis 2015. Life Science Publishing (in Japanese)

16.

Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y, Imanishi Y, Yamakawa T, Ishimura E, Nishizawa Y (2008) Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82:278–287CrossRef

17.

Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y (2008) Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol 69:189–196CrossRef

18.

Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 77:1130–1139CrossRef

19.

Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, Shimizu M, Miki T, Kim M, Nishizawa Y (2002) Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 40:802–809CrossRef

20.

Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M, Takada J, Chaki O, Hagino H, Fukunaga M, Fujiwara S (2019) Executive summary of the Japan Osteoporosis Society Guide for the use of bone turnover markers in the diagnosis and treatment of osteoporosis. Clin Chim Acta 498:101–107CrossRef

21.

Kohno K, Inaba M, Okuno S, Maeno Y, Maekawa K, Yamakawa T, Ishimura E, Nishizawa Y (2009) Association of reduction in bone mineral density with mortality in male hemodialysis patients. Calcif Tissue Int 84:180–185CrossRef

22.

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17:247–288CrossRef

23.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427CrossRef

24.

Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C (2017) Effects of Romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32:181–187CrossRef

25.

Lin ZZ, Wang JJ, Chung CR, Huang PC, Su BA, Cheng KC, Chio CC, Chien CC (2014) Epidemiology and mortality of hip fracture among patients on dialysis: Taiwan national cohort study. Bone 64:235–239CrossRef

26.

Kunizawa K, Kunizawa K, Hiramatsu R, Hoshino J, Mizuno H, Ozawa Y, Sekine A, Kawada M, Sumida K, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Ubara Y, Takaichi K (2020) Denosumab for dialysis patients with osteoporosis: a cohort study. Sci Rep 10:2496CrossRef

27.

Malluche HH, Mawad H, Monier-Faugere MC (2008) Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol 3:S157–S163CrossRef

28.

London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC (2008) Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 19:1827–1835CrossRef

29.

D’Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 85:S73–S78CrossRef

30.

Musci I, Hercz G (1997) Adynamic bone disease: pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens 7:356–361

31.

Kumar M, Shelke D, Shah S (2019) Prognostic potential of markers of bone turnover in delayed-healing tibial diaphyseal fractures. Eur J Trauma Emerg Surg 45:31–38CrossRef

32.

Iwata K, Mashiba T, Hitora T, Yamagami Y, Yamamoto T (2014) A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy. Bone 64:183–186CrossRef

33.

Yamashita J, McCauley LK (2019) Effects of intermittent administration of parathyroid hormone and parathyroid hormone-related protein on fracture healing: a narrative review of animal and human studies. JBMR Plus 3:e10250CrossRef

34.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420CrossRef

35.

Miyaoka D, Inaba M, Imanishi Y, Hayashi N, Ohara M, Nagata Y, Kurajoh M, Yamada S, Mori K, Emoto M (2019) Denosumab improves glomerular filtration rate in osteoporotic patients with normal kidney function by lowering serum phosphorus. J Bone Miner Res 34:2028–2035CrossRef

36.

Kang JH, Keller JJ, Lin HC (2013) Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int 24:271–277CrossRef

37.

Burger D, Levin A (2013) “Shedding” light on mechanisms of hyperphosphatemic vascular dysfunction. Kidney Int 83:187–189CrossRef

38.

Ma L, Zhao S (2017) Risk factors for mortality in patients undergoing hemodialysis: a systematic review and meta-analysis. Int J Cardiol 238:151–158CrossRef

39.

Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M (2019) Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int 30:241–249CrossRef

40.

Yamamoto M, Kawanobe Y, Takahashi H, Shimazawa E, Kimura S, Ogata E (1984) Vitamin D deficiency and renal calcium transport in the rat. J Clin Invest 74:507–513CrossRef

41.

Cavalier E, Souberbielle JC, Delanaye P (2019) PTH determination in hemodialyzed patients—a laboratory perspective. Semin Dial 32:490–492CrossRef

42.

Yajima A, Inaba M, Tominaga Y, Ito A (2007) Minimodeling reduces the rate of cortical bone loss in patients with secondary hyperparathyroidism. Am J Kidney Dis 49:440–451CrossRef

Titel: Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study
verfasst von: Motohiko Sato
Masaaki Inaba
Shinsuke Yamada
Masanori Emoto
Yoshiteru Ohno
Yoshihiro Tsujimoto
Publikationsdatum: 29.07.2021
Verlag: Springer Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 6/2021
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-021-01253-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study